

●▶ **Celltrion**

(FDA)

Celltrion's OMLYCLO® receives FDA approval as the First and Only Interchangeable XOLAIR® Biosimilar

●▶ **H. Lundbeck A/S**

(Approval, EC)

European Commission Approves Lundbeck's Rxulti® for Schizophrenia in Adolescents Aged 13 and Above

●▶ **Amgen**

(Positive Data)

Amgen's UPLIZNA® Shows Significant 52-Week Improvement in Generalized Myasthenia Gravis Patients

●▶ **BioCity Biopharma**

(Collaboration)

BioCity Biopharmaceuticals Collaborates with Merck to Evaluate BC3195 & KEYTRUDA® Combination in Solid Tumors



●► **NS Pharma, Inc.**

(FDA Acceptance, BLA)

FDA Accepts NS Pharma's BLA for Deramiciel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

●► **Akeso**

(NMPA, Approval)

Akeso Received NMPA Approval for Penpulimab in Treating Nasopharyngeal Cancer

●► **Sun Pharma**

(Acquisition)

Sun Pharma to Acquire Checkpoint Therapeutics in \$355 Million Deal, Expanding Oncology Portfolio

